表决结果：9票赞成，0票反对，0票弃权，本议案获表决通过。 证券代码：300685 证券简称：艾德生物 公告编号：2023-044 厦门艾德生物医药科技股份有限公司 第三届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生物"） 第三届董事会第十三次会议于2023年9月8日在厦门市海沧区鼎山路39号公司 会议室以通讯和现场表决相结合的方式召开，会议应到董事9人，实到董事9人， 符合公司章程规定的法定人数。公司监事和高级管理人员列席了本次会议。本次 会议通知于2023年9月5日以电子邮件等形式发出，会议的通知和召开符合《公 司法》与《公司章程》的规定。本次会议由公司董事长LI-MOU ZHENG先生主 持。 二、董事会会议审议情况 1、审议通过《关于公司<2023年限制性股票激励计划（草案）>及其摘要 的议案》 为进一步建立、健全公司长效激励与约束机制，吸引和留住优秀人才，充分 调动公司核心管理人员及核心技术（业务）骨干的积极性，有效地将股东利益、 公司 ...

证券代码：300685 证券简称：艾德生物 公告编号：2023-043 关于公司获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"公司"）于近日获得由 国家药品监督管理局（以下简称"NMPA"）颁发的《中华人民共和国医疗器 械注册证》，具体情况如下： | 产品名称 | 基因测序仪 | | --- | --- | | 型号、规格 | ADx-SEQ200 Plus | | 注册分类 | III类 | | 注册证有效期 | 2023年9月6日至2028年9月5日 | | 注册证编号 | 国械注准20233221286 | | 适用范围 | 该产品采用联合探针锚定聚合测序技术，在临床上用于对来 | | | 源于人体样本中的人脱氧核糖核酸(DNA)或人核糖核酸(RNA) | | | 进行测序，以检测人相关基因序列，这些基因序列可能导致 | | | 疾病或疾病易感性。该仪器在临床上仅限于与药品监督管理 | | | 部门批准的体外诊断试剂以及软件配合使用，不用于人类全 | | | 基因组的测序或从头测序。 ...

证券代码：300685 证券简称：艾德生物 公告编号：2023-042 厦门艾德生物医药科技股份有限公司 关于与阿斯利康达成抗体偶联药物（ADC）伴随诊断合作 的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、合作的情况 1、合作的基本情况 近日，厦门艾德生物医药科技股份有限公司（以下简称"公司"或"艾德生 物"）与AstraZeneca UK Limited（以下简称"阿斯利康"）签署了合作协议 （以下简称"本协议"或"协议"）。公司自主研发的人类10基因突变联合检测 试剂盒（可逆末端终止测序法）1将基于ENHERTU®药物开发伴随诊断用途，用 以筛选HER2（ERBB2）突变阳性的非小细胞肺癌（NSCLC）患者。 2、协议对方的基本情况 阿斯利康是一家全球性生物制药企业，专注于研发、生产及营销处方类药品。 ENHERTU®是一种靶向HER2的抗体偶联药物（ADC），由阿斯利康和第一三 共（TSE:4568）联合开发和商业化。在中国，ENHERTU®获准用于治疗既往接 受过治疗的HER2低表达和HER2阳性的转移性乳腺癌患者。在其他国家， ENHE ...

厦门艾德生物医药科技股份有限公司 关于公司监事近亲属误操作导致短线交易及致歉的公告 截至本公告披露日，杜立威先生持有公司1,440股。 二、本次短线交易的处理情况及公司采取的措施 公司知悉此事后高度重视，并及时核查了解相关情况，公司监事杜琦先生及 其近亲属杜立威先生亦积极配合。本次事项的处理情况及已采取的措施如下： 证券代码：300685 证券简称：艾德生物 公告编号：2023-041 本公司及董事会全体成员保证公告内容的真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门艾德生物医药科技股份有限公司（以下简称"艾德生物"或"公司"） 于近日收到公司监事杜琦先生出具的《关于本人近亲属买卖艾德生物股票的情况 说明及致歉函》，获悉其近亲属杜立威先生于2023年8月8日通过集中竞价方式 卖出并买入公司股票，根据《中华人民共和国证券法》（以下简称"《证券法》"） 《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指 引第10号——股份变动管理》等有关规定，上述交易构成短线交易。现将相关情 况公告如下： 一、本次短线交易的基本情况 | 交易日期 | 交易方向 | 交易股数 | 成交价格 | ...

Financial Performance - The company's operating revenue for the first half of 2023 was CNY 458.71 million, representing a 16.87% increase compared to CNY 392.51 million in the same period last year[23]. - The net profit attributable to shareholders was CNY 126.76 million, up 41.97% from CNY 89.29 million year-on-year[23]. - The net cash flow from operating activities increased by 102.90%, reaching CNY 142.98 million compared to CNY 70.47 million in the previous year[23]. - Basic earnings per share rose to CNY 0.32, a 45.45% increase from CNY 0.22 in the same period last year[23]. - The company achieved a gross profit margin of 90.54% for testing reagents, with a revenue increase of 29.99% year-on-year[64]. - The company reported a significant increase in other income to ¥16,874,165.91, up from ¥6,622,238.55, an increase of 154.1%[153]. - The net profit for the first half of 2023 was ¥126,761,239.87, representing a significant increase of 41.8% from ¥89,560,249.87 in the previous year[153]. - The total revenue from sales of goods and services was CNY 465,519,088.48, compared to CNY 391,739,146.46 in the first half of 2022, marking a growth of 18.8%[160]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1.71 billion, a 3.67% increase from CNY 1.65 billion at the end of the previous year[23]. - The company's equity increased to CNY 1,559,808,625.29 from CNY 1,499,727,525.25, reflecting a growth of approximately 4%[148]. - Total liabilities stood at CNY 151,651,543.91, slightly up from CNY 151,197,385.37, indicating a marginal increase of around 0.3%[148]. - Cash and cash equivalents increased to ¥542,903,804.54, representing 31.72% of total assets, up from 29.96% last year, primarily due to increased sales receipts[68]. - Accounts receivable stood at ¥459,129,431.84, accounting for 26.83% of total assets, a slight decrease of 0.56% from the previous year[68]. - The total amount of financial assets at fair value was ¥259,295,057.48, with a fair value change of ¥3,407,446.03 during the period[70]. - The total liabilities decreased to ¥142,227,934.53 from ¥152,633,923.32, a reduction of 6.8%[153]. Research and Development - The company plans to continue investing in R&D to develop new products that meet market demands, emphasizing the importance of timely product registration and approval[4]. - R&D investment reached CNY 91.87 million in the reporting period, a year-on-year increase of 18.02%, accounting for 20.03% of revenue[52]. - The company has 60 patent authorizations, including 52 invention patents and 8 utility model patents, with core patents authorized in China, the US, the EU, and Japan[52]. - The company’s R&D team comprises 491 professionals across various fields, ensuring a robust and innovative research environment[53]. Market and Competition - The company is focused on continuous product development to meet market demands and maintain competitive advantages in the in vitro diagnostics industry[83]. - The domestic in vitro diagnostic market is expected to grow rapidly, driven by economic development and increasing disposable income, but competition is intensifying, shifting from technology-driven to price-driven[86]. - The company aims to enhance profitability through strict cost control, quality improvement, and capacity utilization, while also expanding its domestic and overseas market share for stable revenue growth[85]. Corporate Governance and Shareholder Information - The company has experienced changes in its board of directors, with new appointments and departures in 2023[91]. - The total number of shares is 398,156,535, with 99.86% being unrestricted shares[129]. - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 22.03% of shares, totaling 87,701,616 shares[132]. - The company completed a share buyback of 3,943,726 shares, accounting for 0.99% of the total share capital, with a total transaction amount of 112 million yuan[129]. - The company did not distribute cash dividends or issue bonus shares for this reporting period[5]. Social Responsibility and Compliance - The company actively engages in social responsibility initiatives, including public awareness campaigns for cancer prevention and early diagnosis[99]. - The company adheres to environmental protection laws and promotes sustainable development practices in its operations[99]. - The financial statements comply with the accounting standards issued by the Ministry of Finance, reflecting the financial status as of June 30, 2023[195].

编号：2023-002 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系活 | 业绩说明会 □媒体采访 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 | | 参与单位名称 | 社会公众投资者 | | 及人员姓名 | | | 时间 | 2023 年 5 月 12 日 14:30~16:15 | | 地点 | 全景网"投资者关系互动平台"（http://rs.p5w.net） | | | 董事、轮值总经理 罗捷敏先生 | | 上市公司接待 | 财务总监、董事会秘书 陈英女士 | | 人员姓名 | | | | 独立董事 蔡宁女士 | | | 1、三年新冠疫情，国内增加了很多体外诊断企业，行业竞争是否变 | | | 成激烈，公司的竞争优势是否还成在？ | | | 您好。疫情期间，公司专注主业，继续聚焦肿瘤精准医疗检测技术的 | | | 创新和产品转化，扎实推进国际化战略，海外收入持续攀升，药企合作硕 | | | 果累累，国内市场虽在 2022 年短期波动，但长期增长趋势没有变化。公 | | | 司的核心竞争力，您可查阅 2022 年年度 ...

Group 1: Event Details - The annual performance briefing will be held on May 12, 2023, from 14:30 to 16:15 [1] - The event will be conducted online, allowing investors to participate via the "Panjing Roadshow" website, WeChat, or the Panjing Roadshow APP [1] - Company executives will discuss the 2022 performance, governance, development strategy, and operational status during the event [1] Group 2: Participation and Interaction - Investors are encouraged to submit questions in advance via email by May 11, 2023, at 17:00 [2] - The company aims to address commonly raised investor concerns during the performance briefing [2] - Key attendees include the rotating general manager, financial director, and independent director [1] Group 3: Company Assurance - The company and its board members guarantee the accuracy and completeness of the disclosed information [1]

Financial Performance - The company's operating revenue for Q1 2023 was ¥195,164,302.80, a decrease of 5.28% compared to ¥206,049,845.51 in the same period last year[6] - Net profit attributable to shareholders was ¥57,317,259.24, representing an increase of 6.91% from ¥53,614,836.90 year-on-year[6] - Basic earnings per share for the period was ¥0.14, up 7.69% from ¥0.13 in the previous year[6] - Total operating revenue for Q1 2023 was ¥195,164,302.80, a decrease of 5.8% compared to ¥206,049,845.51 in Q1 2022[20] - Net profit for Q1 2023 was ¥57,317,259.24, representing an increase of 7.4% from ¥53,336,627.60 in Q1 2022[22] - Basic and diluted earnings per share for Q1 2023 were both ¥0.14, up from ¥0.13 in the same period last year[23] Cash Flow - The net cash flow from operating activities surged by 141.62% to ¥67,559,006.96, compared to ¥27,961,142.84 in the previous year[6] - Cash inflows from operating activities totaled $231,654,038.82, compared to $198,916,694.38 in the prior period, indicating an increase of about 16.5%[24] - Cash outflows from operating activities decreased to $164,095,031.86 from $170,955,551.54, reflecting a reduction of approximately 4.7%[24] - The net cash flow from investing activities was negative at -$88,181,521.96, compared to -$140,286.55 in the previous period, showing a significant improvement[25] - The net cash flow from financing activities was -$13,392,007.96, an improvement from -$17,034,520.27 in the previous period, indicating a reduction in cash outflow by about 21.5%[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,671,421,950.98, reflecting a 1.24% increase from ¥1,650,924,910.62 at the end of the previous year[6] - The total current assets at the end of the first quarter amounted to ¥1,306,200,106.03, an increase from ¥1,285,141,149.89 at the beginning of the year, reflecting a growth of approximately 1.8%[17] - Total liabilities decreased to ¥126,695,415.85 from ¥151,197,385.37, a reduction of 16.2%[19] - The company reported a significant increase in other non-current assets by 55.78% to ¥12,884,143.57, primarily due to increased equipment procurement prepayments[10] Shareholder Information - The total number of shares held by the top 10 unrestricted shareholders is 299,000,000 shares, with the largest shareholder holding 87,701,616 shares, accounting for 22.03%[13] - The company has a total of 607,499 shares under lock-up at the end of the period, with 37,969 shares newly restricted[15] Government Support and Investments - The company received government subsidies amounting to ¥11,895,115.39, a significant increase of 399.63% compared to ¥2,380,790.56 in the previous year[10] - The company’s investment income showed a loss of ¥1,486,582.20, a decline of 183.77% due to losses from joint ventures[10] - Research and development expenses for Q1 2023 were ¥36,988,744.69, slightly down from ¥38,760,861.03 in Q1 2022[20] Management Outlook - The company is focused on expanding its market presence and developing new products, although specific figures were not disclosed in the report[15] - The management indicated a positive outlook for the upcoming quarters, emphasizing strategic investments and potential acquisitions to enhance growth[15]

Financial Performance - The company's operating revenue for 2022 was ¥842,180,427.77, a decrease of 8.16% compared to ¥917,033,391.28 in 2021[23] - The net profit attributable to shareholders for 2022 was ¥263,743,023.32, an increase of 10.09% from ¥239,573,622.91 in 2021[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥156,986,572.23, a decrease of 27.21% compared to ¥215,656,757.15 in 2021[23] - The basic earnings per share for 2022 was ¥0.67, compared to ¥1.09 in 2021, reflecting a decrease of 38.5%[23] - The total assets at the end of 2022 amounted to ¥1,650,924,910.62, an increase of 8.62% from ¥1,519,881,333.25 at the end of 2021[23] - The net assets attributable to shareholders at the end of 2022 were ¥1,499,727,525.25, a rise of 9.90% from ¥1,364,580,687.78 at the end of 2021[23] - The net cash flow from operating activities for 2022 was ¥149,036,792.06, down 11.37% from ¥168,161,324.14 in 2021[23] - The weighted average return on net assets for 2022 was 18.42%, a decrease of 0.77% from 19.19% in 2021[23] Market and Product Development - The company has received approval for 24 types of single-gene and multi-gene tumor testing products, making it a leading enterprise in the industry with the most comprehensive product offerings[34] - The company has applied for over 60 invention patents, with 49 patents granted, highlighting its commitment to innovation and technology development[35] - The company is focusing on precision diagnostics in oncology, which is expected to see increased demand due to rising cancer rates and an aging population[33] - The company has developed a comprehensive companion diagnostic product system that covers targeted therapy and immunotherapy, enhancing its market position[34] - The company is actively pursuing market expansion and product innovation, with several products already approved for reimbursement in local healthcare systems[35] - The company has developed a rich line of LDT products in accordance with Class III IVD product development standards, including HRR and HRD products for guiding cancer treatments[36] - The company has established partnerships with major pharmaceutical companies for companion diagnostics, enhancing clinical trial success rates[52] Research and Development - The company has invested significantly in R&D, developing advanced technologies and holding multiple patents in precision oncology diagnostics[58] - The company invested CNY 174.53 million in R&D, representing a year-on-year increase of 11.79% and accounting for 20.72% of total revenue[62] - The company’s R&D team consists of 465 professionals, ensuring a multidisciplinary approach to innovation[63] - The company has a structured approach to governance, ensuring that compensation aligns with performance metrics and industry standards[150] Regulatory and Compliance - The company emphasizes innovation and compliance, aligning with regulatory requirements and industry trends to meet clinical demands for accurate and rapid diagnostics[37] - The company has received regulatory approval for multiple companion diagnostic products, including ROS1 and PCR-11, which are also covered by local health insurance in Japan[40] - The company has successfully completed the renewal of registration for several Class III medical devices, ensuring compliance with regulatory standards[44] - The company has obtained registration for 68 in vitro diagnostic reagent products classified as Class I[47] - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency and fairness in shareholder meetings[118] Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no interference in its operational decisions[119] - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[120] - The company has established a performance evaluation and incentive system for senior management, ensuring transparency and compliance with laws and regulations[123] - The company emphasizes investor relations management, ensuring transparent communication with shareholders through various channels[124] Social Responsibility and Community Engagement - The company has conducted a public health project, providing free low-dose spiral CT lung cancer screenings for over 3,000 high-risk patients[182] - The company has actively participated in social responsibility initiatives, aligning economic benefits with social and environmental goals[180] - The company emphasizes teamwork and collaboration, aiming for mutual benefits among society, customers, employees, and shareholders[183] Financial Management - The company has a cash dividend policy that aligns with its articles of association, with a cash dividend of 1.4 yuan per 10 shares (including tax) proposed for distribution[166] - The total cash dividend amount (including other methods) is 155,169,115.64 yuan, which accounts for 100% of the total profit distribution[166] - The company has a significant increase in government subsidies, contributing ¥20,075,855.92, or 7.02% of total profit[93] Internal Controls - The company maintained effective internal controls with no significant defects identified in financial and non-financial reporting during the reporting period[175] - The internal control evaluation report indicated that 100% of the total assets and operating income of the evaluated units were included in the company's consolidated financial statements[175] - The company plans to continuously update its internal control measures in line with business expansion to enhance employee awareness of internal controls[173]

Financial Performance - The company's revenue for Q3 2022 was CNY 206.75 million, a decrease of 16.22% compared to CNY 246.78 million in the same period last year[5]. - Net profit attributable to shareholders for Q3 2022 was CNY 134.87 million, an increase of 106.75% from CNY 65.23 million year-on-year[5]. - Basic earnings per share for Q3 2022 increased by 112.50% to CNY 0.34 from CNY 0.16 in the same period last year[6]. - Total operating revenue for Q3 2022 was CNY 599,258,982.80, a decrease of 7.2% compared to CNY 645,735,626.15 in Q3 2021[22]. - The net profit for Q3 2022 was CNY 224,157,836.85, an increase of 27% compared to CNY 176,496,035.76 in Q3 2021[23]. - The total comprehensive income for the period was CNY 224,506,263.64, compared to CNY 176,068,226.97 in the previous year[23]. - The total profit before tax was CNY 255,655,771.92, an increase from CNY 196,187,785.20 in Q3 2021[23]. Assets and Liabilities - Total assets as of the end of the reporting period were CNY 1.63 billion, reflecting a growth of 7.34% from CNY 1.52 billion at the beginning of the year[6]. - Total assets reached CNY 1,631,372,496.37, up from CNY 1,519,881,333.25 at the start of the year, indicating growth in the company's asset base[20]. - Total liabilities decreased to CNY 149,736,431.01 from CNY 150,250,223.95, reflecting improved financial management[20]. - The company's equity attributable to shareholders increased to CNY 1,481,636,065.36 from CNY 1,364,580,687.78, demonstrating strong retained earnings[20]. Cash Flow - Cash and cash equivalents decreased by 200.80% to -¥29,921,267.86, mainly due to an increase in unrealized financial products[12]. - The cash flow from operating activities showed a net increase of CNY 95,723,486.86, down from CNY 124,291,686.18 in the same period last year[24]. - The company reported a decrease in cash and cash equivalents, ending the period with CNY 205,867,355.89, compared to CNY 351,613,750.41 at the end of the previous year[25]. - Net cash flow from investment activities improved by 28.16% to -¥54,574,928.34, driven by cash received from the transfer of SDC2 products[12]. - The net cash flow from financing activities decreased by 87.27% to -¥100,863,405.50, primarily due to increased cash used for share repurchases[12]. - The net cash flow from financing activities was negative at CNY -100,863,405.50, compared to CNY -53,858,840.69 in the same period last year[25]. Operational Highlights - The company completed the delivery of materials related to the SDC2 product and the transfer of intellectual property rights, resulting in a non-operating income of CNY 94.48 million[7]. - The company completed the transfer of SDC2 product rights and the equity of its subsidiary, Aizhiwei, with the necessary approvals obtained[17]. - Total operating costs for Q3 2022 were CNY 452,266,245.86, down from CNY 457,191,133.58 in the same period last year, reflecting a cost reduction strategy[22]. - Research and development expenses increased to CNY 121,508,871.96, up from CNY 109,167,134.77, indicating a focus on innovation[22]. - Operating profit for Q3 2022 was CNY 256,234,697.00, compared to CNY 197,012,147.36 in Q3 2021, showing a significant improvement[22]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 21,998[13]. - The largest shareholder, Forward Investment (Hong Kong) Limited, holds 22.03% of shares, totaling 87,701,616 shares[13]. Investment and Income - Investment income increased by 145.17% to ¥6,835,699.20 due to higher returns from matured financial products[12]. - Fair value changes in investment decreased by 97.83% to ¥48,272.54, primarily due to unrealized changes in financial products[12]. - Asset disposal income surged by 5219.51% to ¥94,550,129.44, attributed to the transfer of SDC2 products and related intellectual property[12]. - Income tax expenses rose by 59.95% to ¥31,497,935.07, mainly due to increased earnings from the transfer of SDC2 products[12]. - The company experienced a foreign exchange gain of CNY 29,793,579.12 during the quarter[25]. Future Outlook - Future outlook includes continued investment in R&D and potential market expansion strategies to enhance competitive positioning[22].